Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:MNKD
Date8/2004
Raised
Post IPO Valuation

General Information

Websitemannkindcorp.com
Twitter@MannKindCorp
CategoryBioTech
Phone661-775-5300
Employees

Offices

Valencia, USA
28903 North Avenue Paine
Valencia, CA, 91355
USA

People

President and Chief Operating Officer, Board of Directors
Board of Directors
Board of Directors
Board of Directors
Board of Directors
Corporate Vice President & Chief Financial Officer
Chairman and Chief Executive Officer
Corporate Vice President of Operations and Chief Technology Officer
Show All People

Funding

DEBT TOTAL $200M
Debt, 7/2013
$160M
Debt, 8/2013
$40M

Tags

MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R) , is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.

Recent Milestones

Videos

Screenshots

MannKind Corporation screenshot
Above: Home Page
Uploaded: 7/1/13

Stock Price

Sources

  1. MannKind Announces $160 Million Debt Financing (online.wsj.com) [edit]
  2. MannKind Satisfies Conditions for Second Tranche of Convertible Note Financing (news.mannkindcorp.com) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy